Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

New Australian Drug Developer Lists on ASX

Published: Thursday, April 05, 2012
Last Updated: Thursday, April 05, 2012
Bookmark and Share
Phase IIb clinical trial results, due mid 2012, looking to expedite global licensing and sales deals.

Following the merger of private drug developer Hunter Immunology Limited with Probiomics Limited, the merged entity has recommenced trading on the Australian Securities Exchange (ASX).

The business will initially continue to trade as Probiomics (ASX: PCC) and intends to rename as Bioxyne in coming weeks.

At the commencement of trading, the company had a market cap of over $33 million with 149.9 million shares.

The largest shareholder is Phillip Asset Management’s IB Australia Bioscience Fund with 31 million shares or 21 percent of the company.

Other top 10 shareholders include respected funds manager Chris Cuffe, biotechnology investor and funds manager Chris Abbott and Hunter Immunology co-founders Professor Robert Clancy and Dr Philip Comans.

In the lead up to the merger and relisting, Probiomics raised $2.4 million at a price of $0.22 cents per share post consolidation. The company has no debt and adequate cash reserves to complete the clinical trial and engage in negotiations with potential partners.

Mr David Radford former Chief Executive Officer of Hunter Immunology and now CEO of Probiomics, said “Our business is now ideally positioned with a supportive capital backing and an institutional shareholder base to take maximum advantage of both short term and long term growth opportunities.”

The Company’s main asset, originating from Hunter Immunology, is a new Australian-developed drug called HI-164OV aimed at treating chronic obstructive pulmonary disease (COPD) which includes bronchitis and emphysema.

Mr Radford said before the merger, Probiomics was a company marketing a range of probiotics experiencing limited sales. Mr Radford said Hunter Immunology decided it would make sense to take over the company with a related type business it could back itself into rather than an IPO.

“Management’s goal is the creation of solid, financially beneficial relationships with global pharmaceutical partner organizations to expedite the commercialization of our lead drug asset HI-164OV” he said.

A number of global pharmaceutical companies have expressed interest in a potential commercial partnership with the company pending the mid 2012 release of final results from a 320-patient Phase IIb clinical trial of HI-164OV.

“A positive result in June that demonstrates efficacy in patients with COPD will position our company as an attractive acquisition or as a potential partner for a number of multinational pharmaceutical companies seeking to expand their portfolios in respiratory vaccine markets,” Mr Radford said.

Mr Radford said there was no cure for COPD, but reducing hospital admissions was crucial and preventing exacerbations was the main focus of therapy worldwide. COPD therapeutics is a major target of global pharmaceutical company research.

“A reduction of at least 10 per cent in the number of patients readmitted to hospital for treatment would be considered a successful result and would have a meaningful impact on the cost of healthcare worldwide to treat COPD, which is currently estimated to cost the US healthcare system $29 billion every year in direct costs. Any therapy that can help reduce healthcare costs will be highly attractive to global pharmaceutical companies,” he said.

A small Phase IIa study in severe COPD patients showed the vaccine prevented hospitalization rates by 90 per cent while reducing the use of steroids, antibiotics and bronchodilators.

The data showed there were also large reductions in the use of corticosteroids (63 per cent) and antibiotics (72 per cent) for treating exacerbations.

Mr Radford said while there may be potential short-term upside from the release of the clinical data, the company was seeking to exploit a number of important new growth opportunities based on the same drug technology platform.

There has already been interest in the long term potential value of the Company’s proprietary mucosal immunology base drug technology.

“These commercial opportunities involve several new therapeutic applications for a number of common human infections such as asthma and middle ear infection,” he said.

He said Probiomics already had raised awareness of the new strategy and potential among the investment community and has a sympathetic shareholder base.

The new Board is led by Chairman Ian Mutton, alongside CEO David Radford, with non-executive directors Doug Wilson, William Harrison, Jeremy Curnock Cook, Glenn Crisp and Patrick Ford.

CEO David Radford was previously CEO of Australian-based developer of infection control technology Nanosonics Limited where he increased substantially the value of the company through successfully securing a global marketing and distribution deal with GE Healthcare.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos